TW201794B - - Google Patents

Download PDF

Info

Publication number
TW201794B
TW201794B TW081100950A TW81100950A TW201794B TW 201794 B TW201794 B TW 201794B TW 081100950 A TW081100950 A TW 081100950A TW 81100950 A TW81100950 A TW 81100950A TW 201794 B TW201794 B TW 201794B
Authority
TW
Taiwan
Prior art keywords
gene
virus
bacteria
plastid
plastids
Prior art date
Application number
TW081100950A
Other languages
English (en)
Chinese (zh)
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of TW201794B publication Critical patent/TW201794B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
TW081100950A 1991-05-03 1992-02-11 TW201794B (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69570691A 1991-05-03 1991-05-03

Publications (1)

Publication Number Publication Date
TW201794B true TW201794B (enExample) 1993-03-11

Family

ID=24794162

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081100950A TW201794B (enExample) 1991-05-03 1992-02-11

Country Status (16)

Country Link
US (2) US5919663A (enExample)
EP (1) EP0512260B1 (enExample)
JP (1) JP3320095B2 (enExample)
KR (1) KR100242798B1 (enExample)
AT (1) ATE202800T1 (enExample)
AU (1) AU654347B2 (enExample)
CA (1) CA2067862C (enExample)
DE (1) DE69231907T2 (enExample)
DK (1) DK0512260T3 (enExample)
ES (1) ES2160573T3 (enExample)
FI (1) FI111013B (enExample)
GR (1) GR3036487T3 (enExample)
IL (1) IL101751A0 (enExample)
NO (1) NO314043B1 (enExample)
PT (1) PT512260E (enExample)
TW (1) TW201794B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI764088B (zh) * 2019-02-26 2022-05-11 南韓商Ｃｊ第一製糖股份有限公司 新穎啟動子及使用該啟動子產生嘌呤核苷酸之方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US7279313B2 (en) * 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
JP2001500008A (ja) * 1996-09-04 2001-01-09 ビーエーエスエフ アクチェンゲゼルシャフト アデニロスクシナート・シンセターゼ
US6010705A (en) * 1997-04-11 2000-01-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Attenuated, invasive vaccines against fish pathogens
WO1998046725A2 (en) * 1997-04-11 1998-10-22 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Attenuated, invasive vaccines against fish pathogens
EP1169465B1 (en) * 1998-12-04 2006-03-01 University Of Manitoba Two-step immunization procedure against chlamydia infection
KR100427587B1 (ko) * 2001-01-12 2004-04-27 주식회사 바이오리더스 신규 ｄ-글루탐산 합성효소 유전자 ｄｎａ 및 이를 이용한 항생제 비의존성 벡터
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
WO2003063786A2 (en) * 2002-01-31 2003-08-07 Symbigene, Inc. Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
CN1276076C (zh) * 2004-12-14 2006-09-20 华东理工大学 一种鳗弧菌野生毒株的无标记基因缺失减毒突变株及其应用
WO2009025888A2 (en) 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
US20100317084A1 (en) * 2007-05-10 2010-12-16 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens
WO2009046449A1 (en) 2007-10-05 2009-04-09 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
WO2010045620A1 (en) * 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US9163219B2 (en) * 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
WO2010135563A1 (en) 2009-05-22 2010-11-25 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
EP2526185A4 (en) 2010-01-22 2013-07-24 Univ Arizona BACTERIUM WITH REGULATED RFAH NUCLEIC ACID
US9598697B2 (en) 2010-05-28 2017-03-21 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
WO2012082946A2 (en) * 2010-12-14 2012-06-21 The Regents Of The University Of California Creation of super-stable coie1 plasmids by duplication of sl 1-4 sequence and point mutations.
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0025118A1 (de) * 1979-08-18 1981-03-18 Riedlinger, Rainer, Dr.-Ing. Anordnung zur akustischen Wiedergabe von Signalen, die mittels eines rechten und eines linken Stereo-Kanals darstellbar sind
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4550081A (en) * 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
DK410783D0 (da) * 1982-09-16 1983-09-09 Benzon A Salfred Fremgangsmade til stabilisering af plasmider
EP0251579A3 (en) * 1986-06-24 1989-03-22 Enterovax Research Pty. Ltd. Non-antibiotic marker system
AU616637B2 (en) * 1986-08-05 1991-11-07 Transgene S.A. Method for the stabilization of a plasmid contained in a bacterial strain and strain obtained
JPS6427477A (en) * 1987-04-01 1989-01-30 Takeda Chemical Industries Ltd Dna and use thereof
US5112749A (en) * 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
GB8730037D0 (en) * 1987-12-23 1988-02-03 Wellcome Found Vaccines
IL93957A0 (en) * 1989-03-31 1990-12-23 Univ Washington Bordetella outer membrane proteins,their use in vaccines and their expression
WO1992011361A1 (en) * 1990-12-18 1992-07-09 The General Hospital Corporation Improved vaccines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI764088B (zh) * 2019-02-26 2022-05-11 南韓商Ｃｊ第一製糖股份有限公司 新穎啟動子及使用該啟動子產生嘌呤核苷酸之方法

Also Published As

Publication number Publication date
FI921940A0 (fi) 1992-04-30
DE69231907D1 (de) 2001-08-09
CA2067862A1 (en) 1992-11-04
US5919663A (en) 1999-07-06
DK0512260T3 (da) 2001-09-17
DE69231907T2 (de) 2001-10-18
ATE202800T1 (de) 2001-07-15
CA2067862C (en) 2003-12-30
FI111013B (fi) 2003-05-15
AU654347B2 (en) 1994-11-03
PT512260E (pt) 2001-12-28
GR3036487T3 (en) 2001-11-30
IL101751A0 (en) 1992-12-30
US5961983A (en) 1999-10-05
EP0512260A2 (en) 1992-11-11
JP3320095B2 (ja) 2002-09-03
FI921940L (fi) 1992-11-04
JPH05192161A (ja) 1993-08-03
NO314043B1 (no) 2003-01-20
EP0512260A3 (en) 1993-07-28
NO921729L (no) 1992-11-04
KR920021701A (ko) 1992-12-18
AU1595992A (en) 1992-11-05
ES2160573T3 (es) 2001-11-16
NO921729D0 (no) 1992-04-30
EP0512260B1 (en) 2001-07-04
KR100242798B1 (ko) 2000-02-01

Similar Documents

Publication Publication Date Title
TW201794B (enExample)
US5631010A (en) Genetically stable cholera vaccines with deletions of ctxA, recA and attRS1
AU640344B2 (en) Novel non-reverting shigella flexneri linve vaccines
Camilli et al. Use of recombinase gene fusions to identify Vibrio cholerae genes induced during infection
EP1135025B1 (en) Plasmid maintenance system for antigen delivery
EP1066375B1 (en) $i(LACTOBACILLI) HARBORING AGGREGATION AND MUCIN BINDING GENES AS VACCINE DELIVERY VEHICLES
Galen et al. Salmonella enterica serovar Typhi live vector vaccines finally come of age
US6537558B2 (en) Methods of producing and using virulence attenuated poxR mutant bacteria
US5643771A (en) Non-reverting live bacterial vaccines
US11000581B2 (en) Engineering gut commensal bacteria to express heterologous proteins in their outer membrane vesicles (OMVs) for delivery to the GI-tract
Barry et al. Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908
JPH11235191A (ja) 細胞の遺伝的集団において所望の組換え遺伝子を維持する方法
HU216449B (hu) Eljárás legyengített baktérium előállítására
Karem et al. Differential induction of carrier antigen-specific immunity by Salmonella typhimurium live-vaccine strains after single mucosal or intravenous immunization of BALB/c mice
EP0465561A1 (en) Avirulent microbes and uses therefor
US5874088A (en) Deletion mutants of cholera vaccines expressing heterologous antigens
Roland et al. Reactogenicity and immunogenicity of live attenuated Salmonella enterica serovar Paratyphi A enteric fever vaccine candidates
Stevenson et al. Use of a rationally attenuated Bordetella bronchiseptica as a live mucosal vaccine and vector for heterologous antigens
WO1991018092A1 (en) Acid-tolerant salmonella typhi, double aro mutants thereof and use as an oral vaccine for typhoid fever
EP1210445B1 (en) Recombinant microorganisms
US20020068067A1 (en) Recombination m. tuberculosis mycobacterium auxotrophic for leucine and vaccines using same
YUAN et al. Removal of Antibiotic Resistance of Live Vaccine Strain Escherichia coli MM‐3 and Evaluation of the Immunogenicity of the New Strain
Wang et al. Construction of a trivalent candidate vaccine against Shigella species with DNA recombination
Strugnell et al. Bacterial Vectors: why have they tailed to deliver?